complex ecosystem in which normal cells of many kinds, including macrophages, lymphocytes, polymorphonuclear leucocytes, fibroblasts and endothelial cells are also commonly involved. Clearly a tumour, in this sense, is always pleoclonal; an important question, to which I shall return, is whether the neoplastic cells are derived from a single cell or from more than one cell.
Some tumours, including some classified as malignant on account of their histological structure or behaviour in tissue culture, appear to have little or no harmful effect for months or years, and occasionally a tumour may, for a time, contribute something useful to the host, for example a necessary hormone. As a rule, however, the symbosis is antagonistic, at least in one direction, and the effect of the tumour on the host can aptly be described as malignant. I do not propose to discuss in detail the manifold ways in which cancer exerts its malign influence, despite the importance of this field of cancer research. I would, however, remind you in passing that they may be both local and systemic, and that the systemic effects include, inter alia, interference with carbohydrate, protein and lipid metabolism, impaired haemopoiesis, excessive production of particular hormones, and impaired immunological function.
While the effect of cancer on the host is often only too apparent, the effect of the host on the tumour is less evident, and this has led to the dogma, which was for a long time accepted uncritically, that malignant tumours are autonomous. It must be emphasized that in speaking of spontaneous regression the qualification spontaneous is used in an operational sense. In some cases infection may have played a role; in others, changes in hormonal balance. Often, however, it is impossible from the published reports to make even a plausible guess as to why rejection occurred, and this highlights the need for detailed study of all cases of regression when they are first observed.
Dormancy.-Many years may elapse between apparently complete removal of a primary tumour and local recurrence or the development of metastases. This occurs particularly in patients with carcinoma of the kidney, breast and ovary, and malignant melanoma. Everson and Cole collected nearly 100 such cases in which local recurrence or metastasis was first recognized 10-50 years after removal of the primary tumour. When the appearance of metastases has been delayed for many years, it is very unlikely that a logarithmic growth curve (for which the specific growth rate is constant) will fit the data, but it may sometimes be possible to fit some other curve such as the Gompertz curve, for which the specific growth rate varies as a continuous function of time. This becomes difficult, however, when, as often happens, the long-delayed metastases grow rapidly, and it seems likely that for much of the time that the patient appeared to be tumour free, the size of the tumourcell population was Wheelock et al. (1981) have stated that tumour dormancy has not been documented in man. Their definition of dormancy requires the existence of some form of growth restraint, but if the case I have just described is excluded on the grounds that no restraining mechanism has been identified, many of the examples of dormancy of animal tumours which they site would also have to be excluded. Several of the animal models reported are of great interest, but I have time to mention only the observation of Eccles and Alexander that the proportion of rats which developed pulmonary tumours within 18 months of amputation of a limb bearing a subcutaneous transplant of a syngeneic fibro-sarcoma, was greatly increased if the rats were exposed to 5 Gy whole-body Xirradiation 1, 7 or 30 days after amputation, or were subjected to 7 days' continuous drainage of the thoracic duct.
Tumour cell population kinetics.-There is convincing evidence that many animal and human tumours contain non-cycling cells, some of which may begin to cycle again. It is also clear that with some tumours there is a high rate of cell loss, so that the tumour may grow slowly despite a high tumour-cell birth rate.
These findings are open to various interpretations, but are consistent with the existence of some form of restraint.
Two questions of great interest, to which I shall return later, are whether the clonal composition of pleoclonal tumours is stable or subject to change, and the extent to which monoclonal tumourcell populations may become heterogeneous.
Immunological evidence.-The proliferation of cancer cells in vitro under a variety of experimental conditions, and sometimes the behaviour of tumours in vivo, may be influenced by immunological, and what I have termed paraimmunological, mechanisms. By immunological, I mean T-cell dependent mechanisms triggered by tumour-associated antigens (TAA), including the subset of TAA known as tumour-associated transplantation antigens (TATA) and the subset of these which I once heard Klein refer to as TAARIPAH (tumourassociated antigens with a rejectioninducing potential in the autochthonous host). Under the heading para-immunological, I include mechanisms which do not fulfil this criterion, but involve macrophages, NK cells and possibly other categories of cell which can also participate in reactions of a strictly immunological kind. I have recently reviewed at some length (Woodruff, If surveillance mechanisms exist, they may fail because the host reaction is ineffective ab initio, which in turn may be due to inherent properties of the tumour, an innate deficiency in the host, or the deleterious effect of the tumour on the host. Alternatively, they may fail due to adaptive changes in the tumour due to clonal selection, mutation and selection, or epigenetic change. Until recently, the possible importance of such changes has attracted surprisingly little attention, owing largely, I believe, to uncritical acceptance of the dogma that the great majority of tumours are monoclonal in origin, and reluctance to accept the possibility of the generation of diversity in a monoclonal tumour cell population, except as a rare event. Growing evidence of the heterogeneous nature of the neoplastic cell component in tumours, which I shall consider towards the end of the lecture, however, confirms my long-standing view that adaptive changes in tumours play an important role in their escape from surveillance.
Limited role of T-dependent surveillance.-The suggestion of Lewis Thomas and MacFarlane Burnett that allograft rejection is a consequence of a mechanism which evolved as a defence against neoplasia implies that this mechanism is T-dependent. The discovery that, with a few exceptions (notably lymphomas and tumours of the skin) the incidence of cancer is not significantly greater in T-deficient hosts than in normal hosts, has shown that the role of T-dependent surveillance is, to say the least, more restricted than originally envisaged. As George and Eva Klein have pointed out, however, the clinical and experimental data are consistent with the proposition that T-mediated surveillance plays an important role in promoting the rejection of cells transformed by ubiquitous oncogenic viruses, including human cells transformed by Epstein-Barr virus. I think myself that it is reasonable to postulate that T-mediated surveillance also eliminates some immunogenic tumours induced by environmental carcinogens, including skin tumours induced by exposure to UV irradiation in sunlight. Clinicians among you will be familiar with the skin tumour known as acanthoma, which occurs on the face, grows rapidly, and is easily misdiagnosed from histological sections as an anaplastic squamous-cell carcinoma, but typically regresses completely either spontaneously or in response to low-dose X-ray therapy. Although I have no evidence, I suspect that this regression is an indication that the tumour is strongly immunogenic.
It is important to distinguish between tumours which are not subject to Tmediated surveillance because they lack TAARIPAH, and those which possess such antigens but escape from surveillance, because in the latter case the search for ways of stopping the escape route may prove rewarding. Possible escape mechanisms include shedding of antigen and antigenic modulation, and specific or non-specific impairment of the host response. These have been discussed many times, so I will confine myself to 3 comments.
The first concerns the work of Margaret Kripke (1981) on UV-induced tumours of mice which, as she has shown, are strongly immunogenic but escape destruction as the result of the action of suppressor T cells. In the light of this discovery, and the work of Benacerraf and others on the effect of UV irradiation on contact-sensitivity reactions, Kripke has drawn attention to two important general principles. First, if the only measure of tumour antigenicity (in the sense of rejection-inducing antigenicity) was the immune response in the autochthonous host, the UV-induced mouse tumours would be classed as non-antigenic. She suggests that much of the difficulty in finding evidence of TSTA in human tumours stems from the fact that we cannot perform the same syngeneic transplantation tests as are used to define these antigens in inbred animals. Secondly, the powerful suppressor activity which permits the escape of UV-induced tumours is evoked by the UV irradiation, and seems to result from a mechanism evolved to protect animals from the dangerous consequences of over-reacting to minor damage to the skin caused by such irradiation. This is a salutary reminder that evolution means compromise, and the fact that surveillance is imperfect reflects the fact that the regulatory pathways described for exogenous antigens also control the immune response to TSTA and TAARIPAH. She suggests that "the failure to view the immune system as a complex homeostatic mechanism, regulated by positive and negative controls, has undoubtedly hindered our progress in the area of cancer immunotherapy. In fact, this deficiency may deserve more responsibility for lack of progress in this area than the convenient argument that human tumours are only weakly antigenic" (Kripke, 1981) .
My second comment about escape mechanisms concerns the suggestion of R. T When we found that the induction of tumours in mice with methylcholanthrene (MC) could, under certain conditions, be delayed and sometimes prevented by repeated treatment with C. parvum (CP) (Woodruff et al., 1 982c) , we postulated that those tumours which did develop in the CP-treated animals would be resistant on transplantation to the therapeutic action of CP, and that their cells would be insensitive in vitro to the cytotoxic action of CP-activated macrophages. When this hypothesis was tested experimentally neither of these predictions was confirmed; we did find, however, that tumours which develop in CP-treated mice in response to a small dose of MC were more immunogenic than those which developed after the same dose of MC in untreated mice (Woodruff et al., 1982b) . Further experiments performed in collaboration with W. H. McBride et al. (1982) have shown no evidence that CP administration during carcinogenesis affects either the proportion or the Fc-receptor avidity of the intra-tumour macrophages, though the Fc-receptor avidity may increase when tumours are passaged in CPtreated mice.
These findings, and the work of others, raise the question of whether intratumour macrophages can be activated during carcinogenesis by agents like CP, and if so whether the activated macro-319 phages have any significant cytotoxic effect on tumour cells in vivo. We have recently developed an experimental model which we hope will help answer these questions. Tumour cells, alone or with macrophages from various sources, are deposited on millipore discs, which are then either cultured in the wells of microtest plates or implanted in mice. It has already become apparent that non-activated macrophages promote the growth of tumour cells on these discs both in vitro, as did tumour macrophages in the system described in this afternoon's symposium by Salmon (1982) , also in vivo; the conditions under which macrophages on implanted discs can be activated, and the further conditions under which activated macrophages on the discs inhibit tumour growth in vivo, have not yet been established.
Are NK cells cytotoxic for tumour cells in vivo?-It is abundantly clear that lymphoid cells from normal, untreated mice, rats and humans may be significantly toxic for syngeneic and allogeneic tumour cells in vitro. It is, I think, also clear from the work of Stutman, Herberman, Burton and others that these cells form a heterogeneous group. Despite this heterogeneity, and my reluctance to disagree with such an acknowledged authority as Dr Stutman on nomenclature, I think there is much to be said for including all these cells under a common label; much as I dislike the word natural in this context (for surely there is no need to remind anyone that these cells are neither unnatural nor supernatural?) I prefer to refer to them all as NK cells.
Some years ago, in experiments performed in collaboration with Noel Warner and Robert Burton, when I was on a sabbatical visit to the Walter and Eliza Hall Institute for Medical Research in Melbourne, we found a strong inverse correlation between the susceptibility of a tumour cell line to in vitro lysis by spleen cells from syngeneic nude mice and its capacity to grow in vivo in such mice. We attributed both these effects to NK cells, which we suggested could be cytotoxic in vivo as well as in vitro. More recent evidence, including some which we have heard about today from Stutman (1982) and Holden (1982) , and have seen in the poster on carcinogenesis in beige mice by Cochran et al. (1982) , points to the same conclusions, but there is still much to be learnt about the contributions of NK cells to surveillance.
Heterogeneity of tumour-cell populations.
-Before concluding I would like to discuss briefly the heterogeneity of tumour cell populations and how it might arise.
It is widely held that most (though admittedly not all) tumours are monoclonal. This may be so if we consider only those tumours which arise under conditions in which the chance of transformation is small, as may indeed quite often be the case with human tumours; under other conditions, however, one would expect to see tumours which are pleoclonal, at least at an early stage in their development. Apart from the special case of plasmacytomas, many of the claims for monoclonality of human tumours are based on studies of tumours in women heterozygous for the gene on the X-chromosome that determines which of the two isoenzymes of glucose-6-phosphate dehydrogenase (G6PD) is produced by a cell. Owing to the inactivation of one X-chromosome in all somatic cells, the normal tissues of these women are mosaics, but this mosaicism should not exist in a monoclonal tumour cell population. Various difficulties in interpretation arise which I do not propose to discuss here; fortunately, the discovery in feral mice of a form (A) of the enzyme phosphoglycerate kinase 1 (PGKl) which differs from the B form found in common laboratory mouse strains, and the development of congenic strains which are homozygous for one or other isoenzyme, has made it possible to study the problem under controlled experimental conditions without the necessity of embarking on a long safari. My colleagues and I have engaged in a study of this kind (Woodruff et al., 1982a) . Not surprisingly, we have confirmed that fibrosarcomas induced in mice with doses of MC which result in tumours in most of the animals, are often pleoclonal. This can be stated categorically, because with several tumours we have isolated both A and B clones, and shown either that these were tumorigenic on transplantation or that they were markedly polyploid.
Three results are of particular interest in present context. First, the extent to which one or other isoenzyme is expressed by a tumour may change dramatically in the course of tissue culture or on transplantation. This raises the possibility that similar changes may occur in the autochthonous host during carcinogenesis and progression, and when a tumour metastasizes or recurs locally after inadequate attempts at ablation. Experimental evidence of the heterogeneity of tumour cells is provided by the work of Poste et al. (1981) on the effect of interactions among clonal subpopulations on the stability of the metastatic phenotype in pleoclonal populations of the B 16 mouse melanoma, and by the work we heard about this morning from Ian Hart (1982) .
Secondly, clones isolated by serial dilution, of which we now have more than 200, are less readily transplantable than uncloned tumour-cell suspensions, and some clones are less readily transplantable than others. This suggests that clones resistant to host defences are selected when a pleoclonal population is transplanted, or that some clones require the cooperation of others to survive. The first hypothesis gains support from our recent observation that clones which fail to grow in normal mice may grow in thymectomized, irradiated mice protected with cytosine arabinoside (as described by Steel et al., 1978) , which were prepared for us by Dr John Hay.
Thirdly, we have isolated from one tumour many subpopulations expressing both enzyme phenotypes. On recloning at extreme dilution (on average 0. I remain convinced that the concept of surveillance in relation to cancer is soundly based, and that advances in the prevention and treatment of cancer will stem from a deeper understanding of the
